Switch theme
Sign up to access all valuation multiples
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
2014
n/a
Last FY Revenue $58.8M
Last FY EBITDA -$2.2M
$26.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pilulka Lekarny achieved revenue of $58.8M and an EBITDA of -$2.2M.
Pilulka Lekarny expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pilulka Lekarny valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $58.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $5.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 9% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -4% | XXX | XXX | XXX |
| EBIT | XXX | -$3.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -7% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.7M | XXX | XXX | XXX |
| Net Margin | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | $1.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pilulka Lekarny's stock price is CZK 202 (or $9).
Pilulka Lekarny has current market cap of CZK 547M (or $24.7M), and EV of CZK 585M (or $26.4M).
See Pilulka Lekarny trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.4M | $24.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pilulka Lekarny has market cap of $24.7M and EV of $26.4M.
Pilulka Lekarny's trades at 0.4x EV/Revenue multiple, and -11.8x EV/EBITDA.
Equity research analysts estimate Pilulka Lekarny's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pilulka Lekarny's P/E ratio is not available.
See valuation multiples for Pilulka Lekarny and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24.7M | XXX | $24.7M | XXX | XXX | XXX |
| EV (current) | $26.4M | XXX | $26.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -11.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPilulka Lekarny's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Pilulka Lekarny's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pilulka Lekarny's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pilulka Lekarny and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pilulka Lekarny acquired XXX companies to date.
Last acquisition by Pilulka Lekarny was XXXXXXXX, XXXXX XXXXX XXXXXX . Pilulka Lekarny acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pilulka Lekarny founded? | Pilulka Lekarny was founded in 2014. |
| Where is Pilulka Lekarny headquartered? | Pilulka Lekarny is headquartered in Czechia. |
| Is Pilulka Lekarny publicy listed? | Yes, Pilulka Lekarny is a public company listed on PRA. |
| What is the stock symbol of Pilulka Lekarny? | Pilulka Lekarny trades under PINK ticker. |
| When did Pilulka Lekarny go public? | Pilulka Lekarny went public in 2020. |
| Who are competitors of Pilulka Lekarny? | Similar companies to Pilulka Lekarny include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Pilulka Lekarny? | Pilulka Lekarny's current market cap is $24.7M |
| Is Pilulka Lekarny profitable? | Yes, Pilulka Lekarny is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
